2016 American Transplant Congress
Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.
Purpose: aHUS often progresses to ESRD and requires transplant (tx). Eculiumab (ECU), a terminal complement inhibitor, inhibits TMA irrespective of tx status. We evaluated outcomes…2016 American Transplant Congress
Early Post Renal Transplant aHUS in Patients with Heterozygous CFHR3-CFHR1 Deletion.
Renal Division, Washington University, Saint Louis, MO.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease with a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Subjects homozygous for…2015 American Transplant Congress
Characteristics and Outcomes of Renal Transplant Recipients With Hemolytic Uremic Syndrome: An OPTN Registry Analysis
Hemolytic uremic syndrome (HUS) accounts for <1% of renal transplants in the US. There is limited data on the characteristics and outcomes of in pediatric…2015 American Transplant Congress
1-Year Safety and Efficacy of Eculizumab in Adult aHUS Patients, With or Without a History of Renal Transplant
Background: Atypical hemolytic-uremic syndrome (aHUS) is a life-threatening, chronic disease of complement-mediated TMA. In aHUS, renal transplantation is associated with post-transplant (TP) TMA and ∼50–70%…
American Transplant Congress abstracts